The EPS projection of ResMed Inc. (NYSE:RMD) for quarter ended 2016-09-30 is $0.67. Last week, the EPS forecast was $0.67 against target of $0.67, a month earlier. Two months ago, this estimate was $0.67 versus forecast of $0.67 three months earlier, implying a deviation of 0%.
ResMed Inc. (NYSE:RMD) stated that 18 days ago, its stock price was positively revised 2 times while negative revisions were 2.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 2, 1, and 2, correspondingly.
EPS estimate downgrade for ResMed Inc. (NYSE:RMD) in the preceding 30, 120, 60 and 90 days were 0, 1, 1, and 1, correspondingly.
ResMed Inc. (NYSE:RMD) EPS target for the quarter closed 3 was $0.67, based on 5 recommendations. As reported on 2016-04-26 the EPS was $0.68. The change was $-0.01, implying a percentage deviation of -1.45%. The projections showed a standard deviation of 0.01.
Quarterly Sales Estimates
ResMed Inc. (NYSE:RMD) yearly sales prediction for the fiscal 2017 stands at $547.283 and the median estimate is at $546.65. Almost 3 analysts issued sales target.
Highest sales target is $550.2 while the lowest target is $545 showing standard deviation of 2.657%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. ResMed Inc. (NYSE:RMD) announced that the deviation in forecast was 6.392%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...